PF-Atlas › Treatments › Dendritic Cell Immunotherapy
Dendritic Cell Immunotherapy
Engineered dendritic cells train immune system to clear fibrotic cells — promotes regulatory T-cell responses
Clinical research — In human clinical trials (Phase I–III). How PF-Atlas grades evidence.
Development stage
Phase I/II (Germany)
Evidence level
Level 2 (Phase I/II)
Mechanism class
Engineered dendritic cells train immune system to clear fibrotic cells — promotes regulatory T-cell responses
Timeline
2-4 years
Risk profile
Low-Medium
Developer
German Centers of Excellence
Key researchers
Multiple
Overview
Pioneered in Germany for IPF. DCs engineered to promote anti-inflammatory and Treg responses. Can halt progression and potentially improve lung function. CD103+ DC-fibroblast crosstalk via TLR9/AHR identified as key fibrogenic pathway (2025). Blocking this reverses scarring signals.
How Dendritic Cell Immunotherapy fits into IPF treatment
Dendritic Cell Immunotherapy is classified as Level 2 (Phase I/II) at the Phase I/II (Germany) stage. Explore how it compares to other options and where it sits in the development pipeline:
Other IPF treatments
Medical disclaimer. This page summarizes published research and PF-Atlas model output about Dendritic Cell Immunotherapy for information only. It is not medical advice or a treatment recommendation. Drug availability, approval status and evidence change — verify with a pulmonologist and official sources (FDA, ClinicalTrials.gov) before any decision.